Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) have been assigned an average rating of “Moderate Buy” from the eighteen ratings firms that are covering the company, MarketBeat reports. Seven investment analysts have rated the stock with a hold recommendation and eleven have given a buy recommendation to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $45.38.

A number of brokerages recently issued reports on TNDM. Royal Bank of Canada decreased their target price on shares of Tandem Diabetes Care from $65.00 to $55.00 and set an “outperform” rating for the company in a research report on Thursday, February 27th. Barclays reduced their price objective on shares of Tandem Diabetes Care from $60.00 to $53.00 and set an “overweight” rating for the company in a research report on Friday, February 28th. Canaccord Genuity Group restated a “buy” rating and set a $63.00 price objective on shares of Tandem Diabetes Care in a research report on Wednesday, February 26th. Citigroup lowered shares of Tandem Diabetes Care from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $35.00 to $24.00 in a research report on Tuesday, March 4th. Finally, Robert W. Baird reduced their price objective on shares of Tandem Diabetes Care from $37.00 to $33.00 and set a “neutral” rating for the company in a research report on Thursday, February 27th.

Tandem Diabetes Care Stock Performance

Shares of TNDM opened at $19.17 on Monday. The firm has a 50-day moving average price of $31.38 and a 200 day moving average price of $34.55. The firm has a market capitalization of $1.27 billion, a PE ratio of -9.93 and a beta of 1.45. The company has a quick ratio of 2.32, a current ratio of 2.90 and a debt-to-equity ratio of 1.29. Tandem Diabetes Care has a 52-week low of $17.64 and a 52-week high of $53.69.

Insider Activity at Tandem Diabetes Care

In related news, COO Jean-Claude Kyrillos purchased 10,538 shares of the stock in a transaction on Friday, March 7th. The shares were bought at an average price of $18.12 per share, for a total transaction of $190,948.56. Following the completion of the acquisition, the chief operating officer now directly owns 10,538 shares in the company, valued at approximately $190,948.56. This trade represents a ∞ increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 2.20% of the company’s stock.

Hedge Funds Weigh In On Tandem Diabetes Care

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Brooklyn Investment Group acquired a new stake in shares of Tandem Diabetes Care in the third quarter worth $28,000. Assetmark Inc. acquired a new stake in shares of Tandem Diabetes Care in the third quarter worth $29,000. AlphaQuest LLC grew its stake in shares of Tandem Diabetes Care by 138.7% in the fourth quarter. AlphaQuest LLC now owns 931 shares of the medical device company’s stock worth $34,000 after acquiring an additional 541 shares during the last quarter. Jones Financial Companies Lllp grew its stake in shares of Tandem Diabetes Care by 195.8% in the fourth quarter. Jones Financial Companies Lllp now owns 1,130 shares of the medical device company’s stock worth $41,000 after acquiring an additional 748 shares during the last quarter. Finally, McIlrath & Eck LLC acquired a new stake in shares of Tandem Diabetes Care in the third quarter worth $52,000.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.